ID   CHP-100L
SY   CHP-100-L; CHP100L; CHP-100 Large
DR   Cosmic; 2228221
DR   Wikidata; Q54813261
RX   PubMed=6825097;
RX   PubMed=25010205;
RX   PubMed=28196595;
RX   PubMed=33460449;
CC   Problematic cell line: Misclassified. Parent cell line (CHP-100) was originally thought to originate from a neuroblastoma but was later shown to be from an Ewing sarcoma.
CC   Part of: MD Anderson Cell Lines Project.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00610.
CC   Doubling time: 21 hours (PubMed=6825097).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=25010205).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His233fs (c.696_697ins4); Zygosity=Unspecified (PubMed=25010205).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Derived from site: In situ; Bone, spine, epidural space; UBERON=UBERON_0003691.
ST   Source(s): PubMed=25010205; PubMed=33460449
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 11,13
ST   D16S539: 10
ST   D18S51: 12,17
ST   D19S433: 13
ST   D21S11: 29
ST   D2S1338: 18,21
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 12,15
ST   TH01: 6,9.3
ST   TPOX: 8,9
ST   vWA: 17,19
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_7166 ! CHP-100
SX   Female
AG   12Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 02-05-24; Version: 11
RX   PubMed=6825097;
RA   Bernal S.D., Thompson R., Gilbert F., Baylin S.B.;
RT   "In vitro and in vivo growth characteristics of two different cell
RT   populations in an established line of human neuroblastoma.";
RL   Cancer Res. 43:1256-1260(1983).
RX   PubMed=25010205; DOI=10.1371/journal.pgen.1004475;
RA   Brohl A.S., Solomon D.A., Chang W., Wang J.-J., Song Y., Sindiri S.,
RA   Patidar R., Hurd L., Chen L., Shern J.F., Liao H.-L., Wen X.-Y.,
RA   Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H.,
RA   Picci P., Triche T.J., Horvai A.E., Miettinen M.M., Wei J.S.,
RA   Catchpoole D., Llombart-Bosch A., Waldman T., Khan J.;
RT   "The genomic landscape of the Ewing sarcoma family of tumors reveals
RT   recurrent STAG2 mutation.";
RL   PLoS Genet. 10:E1004475-E1004475(2014).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=33460449; DOI=10.1002/ijc.33474;
RA   Dirks W.G., Capes-Davis A., Eberth S., Fahnrich S., Wilting J.,
RA   Nagel S., Steenpass L., Becker J.;
RT   "Cross-contamination meets misclassification: awakening of CHP-100
RT   from sleeping beauty sleep -- a reviewed model for Ewing's sarcoma.";
RL   Int. J. Cancer 148:2608-2613(2021).